Corcept Therapeutics Incorporated (CORT)
| Market Cap | 9.37B |
| Revenue (ttm) | 769.10M |
| Net Income (ttm) | 46.68M |
| Shares Out | 107.35M |
| EPS (ttm) | 0.40 |
| PE Ratio | 217.21 |
| Forward PE | 75.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,590,688 |
| Open | 83.72 |
| Previous Close | 84.75 |
| Day's Range | 82.31 - 87.49 |
| 52-Week Range | 28.66 - 91.00 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 88.00 (+0.78%) |
| Earnings Date | Jul 30, 2026 |
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis... [Read more]
Financial Performance
In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $88.0, which is an increase of 0.78% from the latest price.
News
Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome
The company states: “Corcept Therapeutics (CORT) announced it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushin...
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept announces presentation of new data from Catalyst, Momentum trials
Corcept Therapeutics (CORT) announced the presentation of new data from its Catalyst and Momentum trials at the American Diabetes Association’s 86th Scientific Sessions. The presentations underscore t...
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics price target raised to $135 from $110 at Canaccord
Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $135 from $110 and keeps a Buy rating on the shares. The firm Corcept surprised today in reporting they…
Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Corcept Therapeutics (CORT) to $95 from $75 and keeps a Buy rating on the shares. The firm cites the…
Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant
Corcept Therapeutics (CORT) announced it will resubmit its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for relacorilant as a treatment for patients with Cushing’s syndrom...
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics upgraded to Buy from Neutral at UBS
UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a price target of $72, up from $44. The recent approval of Lifyorli in ovarian cancer is expected to drive…
Corcept Therapeutics upgraded to Buy from Neutral at UBS
UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a $72 price target
Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $75 from $60 and keeps a Buy rating on the shares. The firm says Lifyorli and Korlym strength…
Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler
Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $88 from $73 and keeps an Overweight rating on the shares following quarterly results. The firm says it…
Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study
Corcept Therapeutics (CORT) “announced two-year overall survival data from the Phase 2 DAZALS study of its proprietary, selective cortisol modulator dazucorilant in patients with amyotrophic lateral s...
Corcept Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4.9% year-over-year to $164.9M, but net loss reached $31.8M due to launch costs. Lifyorli’s early FDA approval and rapid adoption, plus strong endocrinology growth, led to raised 2026 guidance of $950M–$1.05B.
Corcept Therapeutics Earnings release: Q1 2026
Corcept Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Corcept Therapeutics Quarterly report: Q1 2026
Corcept Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)
Reports Q1 revenue $164.9M, consensus $186.6M. “This quarter’s results include a significant milestone: With the FDA’s approval of Lifyorli (relacorilant) to treat women with platinum-resistant ovaria...
Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
16:27 EDT Corcept Therapeutics (CORT) raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026....
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Proxy statement: Proxy filing
Corcept Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Corcept Therapeutics presents final overall survival data from ROSELLA trial
Corcept Therapeutics (CORT) presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-r...
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...